Butterfly Network (BFLY) Reports Q1 EPS

Butterfly Network, Inc. (NYSE:BFLY) is one of the 8 Best Healthcare AI Stocks to Buy According to Analysts.

On April 30, 2026, Butterfly Network, Inc. (NYSE:BFLY) reported Q1 EPS of (3c), versus consensus estimates of (5c), while revenue rose to $26.5 million from expectations of $25.74 million. CEO Joseph DeVivo said the company delivered a strong start to the year, with 25% revenue growth and continued improvement in gross margins. He said the business is increasingly organized around three growth engines: global expansion of point-of-care ultrasound, the extension of those capabilities into Home & Community Care, and the growth of Butterfly Embedded, which expands the company’s technology beyond traditional ultrasound into new applications. He added that these initiatives are part of a single platform strategy that is beginning to scale.

Butterfly reaffirmed its full-year 2026 revenue guidance of $117 million to $121 million, compared with consensus estimates of $116.62 million, and continues to expect an adjusted EBITDA loss of $21 million to $25 million.

On April 21, 2026, the company appointed Arun Nagdev as Chief Medical Officer for Point-of-Care Ultrasound. In this role, he will lead global medical strategy for the company’s core POCUS business, including clinical validation, customer engagement, and regulatory development. He currently serves as Director of Emergency Ultrasound at Highland General Hospital and as an Associate Clinical Professor at the University of California, San Francisco.

Butterfly Network, Inc. (NYSE:BFLY) develops handheld ultrasound imaging systems, including its Butterfly iQ+ and iQ3 devices, designed to deliver whole-body imaging through a single probe integrated with mobile and hospital-based workflows.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.